The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite
Open accessPublished version of a preprint
Abstract
Snakebite is a medical emergency causing high mortality and morbidity in rural tropical communities that typically experience delayed access to unaffordable therapeutics. Viperid snakes are responsible for the majority of envenomings, but extensive interspecific variation in venom composition dictates that different antivenom treatments are used in different parts of the world, resulting in clinical and financial snakebite management challenges. Here, we show that a number of repurposed Phase 2-approved small molecules are capable of broadly neutralizing distinct viper venom bioactivities in vitro by inhibiting different enzymatic toxin families. Furthermore, using murine in vivo models of envenoming, we demonstrate that a single dose of a rationally-selected dual inhibitor combination consisting of marimastat and varespladib prevents murine lethality caused by venom from the most medically-important vipers of Africa, South Asia and Central America. Our findings support the translation of combinations of repurposed small molecule-based toxin inhibitors as broad-spectrum therapeutics for snakebite.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Practice Guide for Dose Conversion between Animals and Human
Nair, A., & Jacob, S. (2016) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.177703 · Cited by 6,174
Gutiérrez, J. M., Lewin, M. R., Williams, D. J., & Lomonte, B. (2020) · Toxins · doi:10.3390/toxins12020131 · Cited by 92
Research works printed but not linked: 67
- Gutiérrez, J. M. et al. Snakebite envenoming. Nat. Rev. Dis. Prim. 3, 17063 (2017). · DOI · Paper page
- Harrison, R. A., Casewell, N. R., Ainsworth, S. A. & Lalloo, D. G. The time is now: a call for action to translate recent momentum on tackling tropical snakebite into sustained benefit for victims. Trans. R. Soc. Trop. Med. Hyg. 113, 835–838 (2019). · DOI
- Williams, D. J. et al. Strategy for a globally coordinated response to a priority neglected tropical disease: Snakebite envenoming. PLoS Negl. Trop. Dis. 13, e0007059 (2019). · DOI · Paper page
- Casewell, N. R. et al. Medically important differences in snake venom composition are dictated by distinct postgenomic mechanisms. Proc. Natl Acad. Sci. USA 111, 9205–9210 (2014). · DOI · Paper page
- Tasoulis, T. & Isbister, G. K. A review and database of snake venom proteomes. Toxins 9, 290 (2017). · DOI · Paper page
- Williams, D. J. et al. Ending the drought: New strategies for improving the flow of affordable, effective antivenoms in Asia and Africa. J. Proteom. 74, 1735–1767 (2011). · DOI · Paper page
- Arnold, C. Vipers, mambas and taipans: the escalating health crisis over snakebites. Nature 537, 26–28 (2016). · DOI
- Gutiérrez, J. M. Global availability of antivenoms: The relevance of public manufacturing laboratories. Toxins 11, 5 (2019). · doi:10.3390/toxins11010005
- Casewell, N. R. et al. Pre-clinical assays predict pan-African Echis viper efficacy for a species-specific antivenom. PLoS Negl. Trop. Dis. 4, e851 (2010). · DOI
- de Silva, H. A. et al. Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: A randomised, double-blind, placebo-controlled trial. PLoS Med. 8, e1000435 (2011). · DOI · Paper page
- Mohapatra, B. et al. Snakebite mortality in India: a nationally representative mortality survey. PLoS Negl. Trop. Dis. 5, e1018 (2011). · DOI · Paper page
- Bulfone, T. C., Samuel, S. P., Bickler, P. E. & Lewin, M. R. Developing small molecule therapeutics for the initial and adjunctive treatment of snakebite. J. Trop. Med. 2018, 1–14 (2018). · DOI
- Knudsen, C. & Laustsen, A. H. Recent advances in next generation snakebite antivenoms. Trop. Med. Infect. Dis 3, 42 (2018). · DOI
- Habib, A. G., Gebi, U. I. & Onyemelukwe, G. C. Snake bite in Nigeria. Afr. J. Med. &. Med. Sci. 30, 171–178 (2001).
- Otero-Patiño, R. Epidemiological, clinical and therapeutic aspects of Bothrops asper bites. Toxicon 54, 998–1011 (2009). · DOI · Paper page
- Kumar, K. G. S., Narayanan, S., Udayabhaskaran, V. & Thulaseedharan, N. K. Clinical and epidemiologic profile and predictors of outcome of poisonous snake bites – an analysis of 1,500 cases from a tertiary care center in Malabar, North Kerala, India. Int. J. Gen. Med. 11, 209–216 (2018). · DOI
- Slagboom, J., Kool, J., Harrison, R. A. & Casewell, N. R. Haemotoxic snake venoms: their functional activity, impact on snakebite victims and pharmaceutical promise. Br. J. Haematol. 177, 947–959 (2017). · DOI · Paper page
- Gutiérrez, J. M. & Rucavado, A. Snake venom metalloproteinases: their role in the pathogenesis of local tissue damage. Biochimie 82, 841–850 (2000). · DOI · Paper page
- Gutiérrez, J. M., Escalante, T., Rucavado, A. & Herrera, C. Hemorrhage caused by snake venom metalloproteinases: a journey of discovery and understanding. Toxins (Basel). 8, 93 (2016). · DOI · Paper page
- Ferraz, C. R. et al. Multifunctional toxins in snake venoms and therapeutic implications: from pain to hemorrhage and necrosis. Front. Ecol. Evol. 7, 1–19 (2019). · DOI · Paper page
- Howes, J.-M., Theakston, R. D. G. & Laing, G. D. Neutralization of the haemorrhagic activities of viperine snake venoms and venom metalloproteinases using synthetic peptide inhibitors and chelators. Toxicon 49, 734–739 (2007). · DOI
- Lewin, M., Samuel, S., Merkel, J. & Bickler, P. Varespladib (LY315920) appears to be a potent, broad-spectrum, inhibitor of snake venom phospholipase A2 and a possible pre-referral treatment for envenomation. Toxins 8, 248 (2016). · DOI · Paper page
- Arias, A. S., Rucavado, A. & Gutiérrez, J. M. Peptidomimetic hydroxamate metalloproteinase inhibitors abrogate local and systemic toxicity induced by Echis ocellatus (saw-scaled) snake venom. Toxicon 132, 40–49 (2017). · DOI
- Rucavado, A. et al. Inhibition of local hemorrhage and dermonecrosis induced by Bothrops asper snake venom: effectiveness of early in situ administration of the peptidomimetic metalloproteinase inhibitor batimastat and the chelating agent CaNa2EDTA. Am. J. Trop. Med. Hyg. 63, 313–319 (2000). · DOI
- Ainsworth, S. et al. The paraspecific neutralisation of snake venom induced coagulopathy by antivenoms. Commun. Biol. 1, 34 (2018). · DOI
- Lewin, M. et al. Delayed LY333013 (Oral) and LY315920 (Intravenous) reverse severe neurotoxicity and rescue juvenile pigs from lethal doses of Micrurus fulvius (Eastern coral snake) venom. Toxins 10, 479 (2018). · DOI
- Lewin, M. et al. Delayed oral LY333013 rescues mice from highly neurotoxic, lethal doses of Papuan taipan (Oxyuranus scutellatus) venom. Toxins 10, 380 (2018). · DOI
- Albulescu, L.-O. et al. Preclinical validation of a repurposed metal chelator as an early-intervention therapeutic for hemotoxic snakebite. Sci. Trans. Med. 12, eaay8314 (2020). · DOI
- Wang, Y. et al. Exploration of the inhibitory potential of varespladib for snakebite envenomation. Molecules 23, 391 (2018). · DOI
- Layfield, H. J. et al. Repurposing cancer drugs batimastat and marimastat to inhibit the activity of a group I metalloprotease from the venom of the Western diamondback rattlesnake, Crotalus atrox. Toxins 12, 309 (2020). · DOI
- Rowsell, S. et al. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J. Mol. Biol. 319, 173–181 (2002). · DOI · Paper page
- Warrell, D. A. & Arnett, C. The importance of bites by the saw scaled or carpet viper (Echis carinatus): Epidemiological studies in Nigeria and a review of the world. Acta Trop. 33, 307–341 (1976).
- Warrell, D. in Handbook of Clinical Toxicology of Animal Venoms and Poisons (eds White, J. & Meier, J.) pp 534–594 (CRC Press, 1995).
- Warrell, D. in Handbook of Clinical Toxicology of Animal Venoms and Poisons (eds. White, J. & Meier, J.) pp 455–492 (CRC Press, 1995).
- Still, K. et al. Multipurpose HTS Coagulation Analysis: Assay Development and Assessment of Coagulopathic Snake Venoms. Toxins 9, 382 (2017). · DOI
- Rogalski, A. et al. Differential procoagulant effects of saw-scaled viper (Serpentes: Viperidae: Echis) snake venoms on human plasma and the narrow taxonomic ranges of antivenom efficacies. Toxicol. Lett. 280, 159–170 (2017). · doi:10.1016/j.toxlet.2017.08.020
- Slagboom, J. et al. High throughput screening and identification of coagulopathic snake venom proteins and peptides using nanofractionation and proteomics approaches. PLoS Negl. Trop. Dis. 14, e0007802 (2020). · DOI
- Winer, A., Adams, S. & Mignatti, P. Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes. Mol. Cancer Ther. 17, 1147–1155 (2018). · DOI · Paper page
- Kim, E. Y. et al. Low-dose nafamostat mesilate in hemodialysis patients at high bleeding risk. Kidney Res. Clin. Pract. 30, 61–66 (2011).
- Kim, H. S. et al. Cardiac arrest caused by nafamostat mesilate. Kidney Res. Clin. Pract. 35, 187–189 (2016). · doi:10.1016/j.krcp.2015.10.003
- Theakston, R. D. & Reid, H. A. Development of simple standard assay procedures for the characterization of snake venom. Bull. World Health Organ. 61, 949–956 (1983).
- Harrison, R. A. et al. Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa. PLoS Negl. Trop. Dis. 11, e0005969 (2017). · DOI
- Bolaños, R. Toxicity of Costa Rican snake venoms for the white mouse. Am. J. Trop. Med. Hyg. 21, 360–363 (1972). · DOI
- Villalta, M. et al. Development of a new polyspecific antivenom for snakebite envenoming in Sri Lanka: Analysis of its preclinical efficacy as compared to a currently available antivenom. Toxicon 122, 152–159 (2016). · DOI
- Mora-Obando, D. et al. Proteomic and functional profiling of the venom of Bothrops ayerbei from Cauca, Colombia, reveals striking interspecific variation with Bothrops asper venom. J. Proteom. 96, 159–172 (2014). · DOI
- Harrison, R. A. & Gutiérrez, J. M. Priority actions and progress to substantially and sustainably reduce the mortality, morbidity and socioeconomic burden of tropical snakebite. Toxins 8, 351 (2016). · DOI
- de la Rosa, G. et al. Horse immunization with short-chain consensus α-neurotoxin generates antibodies against broad spectrum of elapid venomous species. Nat. Commun. 10, 3642 (2019). · DOI
- Kini, R. M., Sidhu, S. S. & Laustsen, A. H. Biosynthetic oligoclonal antivenom (BOA) for snakebite and next-generation treatments for snakebite victims. Toxins 10, 534 (2018). · DOI
- Laustsen, A. H. et al. In vivo neutralization of dendrotoxin-mediated neurotoxicity of black mamba venom by oligoclonal human IgG antibodies. Nat. Commun. 9, 3928 (2018).
- Peterson, J. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc. Res. 69, 677–687 (2006). · DOI · Paper page
- Millar, A. W. et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br. J. Clin. Pharmacol. 45, 21–26 (1998). · doi:10.1046/j.1365-2125.1998.00639.x
- Rosemurgy, A. et al. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am. J. Clin. Oncol. 22, 247–252 (1999). · DOI
- Adis R&D Profile. Varespladib. Am. J. Cardiovasc. Drugs 11, 137–143 (2011). · DOI · Paper page
- Rosenson, R. S. et al. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J. Am. Coll. Cardiol. 56, 1079–1088 (2010). · DOI
- Abraham, E. et al. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Crit. Care Med. 31, 718–728 (2003). · DOI
- Nicholls, S. J. et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: The VISTA-16 randomized clinical trial. JAMA - J. Am. Med. Assoc. 311, 252–262 (2014). · DOI · Paper page
- Ohtake, Y. et al. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib. Nephrol. 93, 215–217 (1991). · doi:10.1159/000420222
- Maiorino, R. M., Xu, Z. F. & Aposhian, H. V. Determination and metabolism of dithiol chelating agents. XVII. In humans, sodium 2,3-dimercapto-1-propanesulfonate is bound to plasma albumin via mixed disulfide formation and is found in the urine as cyclic polymeric disulfides. J. Pharmacol. Exp. Ther. 277, 375–384 (1996).
- Kosnett, M. J. The role of chelation in the treatment of arsenic and mercury poisoning. J. Med. Toxicol. 9, 347–354 (2013). · doi:10.1007/s13181-013-0344-5
- Wagstaff, S. C., Sanz, L., Juárez, P., Harrison, R. A. & Calvete, J. J. Combined snake venomics and venom gland transcriptomic analysis of the ocellated carpet viper, Echis ocellatus. J. Proteom. 71, 609–623 (2009). · DOI
- Tan, N. H. et al. Functional venomics of the Sri Lankan Russell’s viper (Daboia russelii) and its toxinological correlations. J. Proteom. 128, 403–423 (2015). · DOI
- Pla, D. et al. Phylovenomics of Daboia russelii across the Indian subcontinent. Bioactivities and comparative in vivo neutralization and in vitro third-generation antivenomics of antivenoms against venoms from India, Bangladesh and Sri Lanka. J. Proteom. 207, 103443 (2019). · DOI
- Bradley, J. D. et al. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J. Rheumatol. 32, 417–423 (2005).
- Sevenet, P. O. & Depasse, F. Clot waveform analysis: Where do we stand in 2017? Int. J. Lab. Hematol. 39, 561–568 (2017). · DOI
- Patra, A., Kalita, B., Chanda, A. & Mukherjee, A. K. Proteomics and antivenomics of Echis carinatus carinatus venom: Correlation with pharmacological properties and pathophysiology of envenomation. Sci. Rep. 7, 17119 (2017). · DOI
- Alape-Girón, A. et al. Studies on the venom proteome of Bothrops asper: perspectives and applications. Toxicon 54, 938–948 (2009). · DOI
- Calvete, J. J., Escolano, J. & Sanz, L. Snake venomics of Bitis species reveals large intragenus venom toxin composition variation: application to taxonomy of congeneric taxa. J. Proteome Res. 6, 2732–2745 (2007). · DOI
Cited by
Causes and Consequences of Snake Venom Variation
Casewell, N. R., Jackson, T. N. W., Laustsen, A. H., & Sunagar, K. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.05.006 · Cited by 396
Self-citationKazemi, M., Faisal Kabir, S., & Fini, E. H. (2021) · Resources Conservation and Recycling · doi:10.1016/j.resconrec.2021.105776 · Cited by 221
Bittenbinder, M. A., van Thiel, J., Cardoso, F. C., Casewell, N. R., Gutiérrez, J.-M., Kool, J., & Vonk, F. J. (2024) · Communications Biology · doi:10.1038/s42003-024-06019-6 · Cited by 132
Self-citationHall, S. R., Rasmussen, S. A., Crittenden, E., Dawson, C. A., Bartlett, K. E., Westhorpe, A. P., Albulescu, L.-O., Kool, J., Gutiérrez, J. M., & Casewell, N. R. (2023) · Nature Communications · doi:10.1038/s41467-023-43510-w · Cited by 63
Self-citationLiu, J., Wang, L., Xie, M., Zhao, W., Sun, J., Jin, Y., Liu, M., Zhao, J., Cheng, L., Wen, C., et al. (2025) · Redox Report · doi:10.1080/13510002.2025.2507557 · Cited by 13
“Recent findings emphasize that several Phase-2 approved drugs hold therapeutic promise, with varespladib, a PLA 2 inhibitor, emerging as one of the most notable candidates [40].”
Influential
Metadata
- Authors
- Albulescu, L.-O., Xie, C., Ainsworth, S., Alsolaiss, J., Crittenden, E., Dawson, C. A., Softley, R., Bartlett, K. E., Harrison, R. A., Kool, J., & Casewell, N. R.
- Venue
- Nature Communications
- Published
- 2020-12-15
- Volume
- 11
- Issue
- 1
- Pages
- 6094-6094
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W3112999791
- Cited by
- 174
- References
- 2
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-06-24)
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- Wellcome Trust (200517/Z/16/Z)
- RCUK | Medical Research Council (MR/S00016X/1 and CiC19017)
- Royal Society (200517/Z/16/Z)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite. https://app.cochat.ai/papers/10.1038/s41467-020-19981-6
- The paper
- Albulescu, L.-O., Xie, C., Ainsworth, S., Alsolaiss, J., Crittenden, E., Dawson, C. A., Softley, R., Bartlett, K. E., Harrison, R. A., Kool, J., & Casewell, N. R. (2020). A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite. Nature Communications. https://doi.org/10.1038/s41467-020-19981-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.